Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2020-10-09 AGM Information
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
PHARMENA_Ogłoszenie o zwołaniu NWZ w dniu 05 11 2020
AGM Information Classification · 99% confidence The document is titled "Ogłoszenie o zwołaniu Nadzwyczajnego Walnego Zgromadzenia Spółki..." which translates to "Announcement of the convening of an Extraordinary General Meeting of the Company...". It details the date, time, location, and a specific agenda (Porządek obrad) for this meeting, along with detailed instructions for shareholder participation, voting by proxy, and submitting proposals. This content directly relates to the formal procedures and materials surrounding a shareholder meeting, specifically an Extraordinary General Meeting (EGM). The closest matching category is AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM). Although this is an EGM, the nature of the document—the official notice and procedural rules for a general meeting—aligns best with AGM-R compared to other options like Proxy Solicitation (PSI) which is usually the solicitation material itself, or DVA which is the results announcement. Given the context of general meeting notices, AGM-R is the most appropriate classification for the convening announcement.
2020-10-09 Polish
Zwołanie Nadzwyczajnego Walnego Zgromadzenia na dzień 5 listopada 2020 r. - Content (PL)
AGM Information Classification · 98% confidence The document text is in Polish and announces the convening of an Extraordinary General Meeting ('Nadzwyczajnego Walnego Zgromadzenia') scheduled for November 5, 2020. It explicitly states that the Management Board ('Zarząd') is providing the announcement along with draft resolutions ('projektami uchwał') for the meeting. This content directly relates to the preparation and announcement of a shareholder meeting, which falls under the scope of AGM-related materials, specifically the notice calling the meeting. Since the document is short (844 chars) and serves as the official notice/announcement for the meeting, AGM-R (AGM Information) is the most appropriate classification, as it covers materials shared during or related to the AGM.
2020-10-09 Polish
Zamiar przeprowadzenia emisji akcji serii F. - Content (PL)
Capital/Financing Update Classification · 98% confidence The document text discusses the company's plans to finance development projects related to 1-MNA for Sars-Cov-2 treatment. Crucially, it states that the Management Board ('Zarząd') intends to conduct a new share issue ('nowej emisji akcji') worth 1.5 million PLN to fund 'Proof of concept' studies. Furthermore, it explicitly mentions that the Board plans to convene an Extraordinary General Meeting ('nadzwyczajne walne zgromadzenie') on November 5, 2020, to vote on the capital increase via the issuance of Series F shares. This combination of announcing a financing activity (share issue) and the related shareholder meeting preparation points strongly towards a Capital/Financing Update (CAP). While it mentions a future general meeting, the primary focus is the capital raise itself, not the voting results (DVA) or the AGM presentation (AGM-R). It is not a full 10-K or IR, nor is it just a simple announcement of a report (RPA).
2020-10-09 Polish
Informacja o wyborze nowego Przewodniczącego Rady Nadzorczej - Content (PL)
Board/Management Information Classification · 100% confidence The document text, written in Polish, announces a change in the company's supervisory board: the appointment of Mr. Jerzy Gębicki as the Chairman of the Supervisory Board, effective September 30, 2020. This directly relates to changes in senior governance personnel. This aligns perfectly with the definition of Board/Management Information (MANG). The document is short (702 characters) and is a direct announcement of a management change, not a summary or a link to a larger report.
2020-10-01 Polish
Oświadczenie Zarządu w sprawie rzetelności jedn i skons spr fin I Q 2020
Management Reports Classification · 99% confidence The document is titled "OŚWIADCZENIE ZARZĄDU W SPRAWIE RZETELNOŚCI JEDNOSTKOWEGO I SKONSOLIDOWANEGO SPRAWOZDANIA FINANSOWEGO ZA I POŁROCZE 2020" (Management Statement on the Reliability of the Individual and Consolidated Financial Statements for the First Half of 2020). This is a formal declaration by the management regarding the accuracy and fairness of the semi-annual financial statements. This content is characteristic of the Management's Discussion and Analysis (MDA) section, which often includes such management assertions about the accompanying financial reports. Since it is a statement about the financial results for a period shorter than a year ("I półrocze" - first half), it strongly aligns with the content expected in an Interim/Quarterly Report (IR) or the associated management commentary (MDA). Given the explicit focus on management's assessment of the financial statements for the half-year period, MDA is the most precise fit for this specific management assertion document, although it is closely related to the IR filing itself. The document is short (943 chars) and is a direct management statement, not an announcement of a full report release.
2020-08-28 Polish
Oświadczenie Zarządu w sprawie podmiotu uprawnionego do badania spr fin
Audit Report / Information Classification · 99% confidence The document is a formal declaration ('OSWIADCZENIE ZARZĄDU') from the Management Board of PHARMENA S.A. dated August 28, 2020. The content explicitly states the selection of the auditing firm responsible for reviewing the semi-annual condensed individual and consolidated financial statements for the first half of 2020 ('badanie półrocznego skróconego jednostkowego i skonsolidowanego sprawozdania finansowego za I półrocze 2020'). This declaration concerns the audit process and the auditor's qualifications, not the audit report itself, nor is it the full Annual Report (10-K) or a comprehensive Interim Report (IR). It is a specific declaration related to the audit process. This fits best under Audit Report / Information (AR), as it directly relates to the audit process and principles applied, even though it is a declaration about the auditor selection rather than the final audit opinion. H1 2020
2020-08-28 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.